Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn’s Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS: Vedolizumab is effective and safe for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Little is known about the incidence rate of loss of response to vedolizumab maintenance therapy or whether dose intensification restores response to this drug. METHODS: We searched PubMed, Scopus and conference abstracts (Digestive Disease Week, European Crohn's and Colitis Organization, and United European Gastroenterology Week), through December 2017, for experimental or observational cohort studies of vedolizumab use in adult patients with CD or UC; we identified studies that provided sufficient data to determine the incidence rate of loss of response among initial responders and the ability of dose intensification to restore response. Two reviewers independently abstracted study data and outcomes and rated each study's risk of bias. The studies were evaluated for heterogeneity and publication bias. Summary estimates were calculated using random effects models. RESULTS: We analyzed data from 10 eligible cohorts; most patients had received prior treatment with a tumor necrosis factor antagonist. The pooled incidence rates of loss of response were 47.9 per 100 person‐years of follow up (95% CI, 26.3–87.0; I2 = 74%) among patients with CD and 39.8 per 100 person‐years of follow up (95% CI, 35.0–45.3; I2 = 0%) among patients with UC. Dose intensification restored response to the drug in 53.8% of secondary non‐responders (95% CI, 21.8%‐82.9%; I2 = 77%). CONCLUSIONS: In a systematic review and meta‐analysis, we found high proportions of patients with CD or UC to lose responsiveness to vedolizumab maintenance therapy. Dose intensification restores responsiveness to more than half of these patients. Additional studies are warranted to inform clinical decision making.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
The combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380
Development of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026
A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY
Harvey, R. F., & Bradshaw, J. M. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92767-1 · Cited by 2,959
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J.-F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,888
Self-citationVedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Colombel, J.-F., Sands, B. E., Rutgeerts, P., Sandborn, W., Danese, S., D'Haens, G., Panaccione, R., Loftus, E. V., Sankoh, S., Fox, I., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-311079 · Cited by 806
Self-citationLoss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Gisbert, J. P., & Panés, J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.88 · Cited by 664
On tests of the overall treatment effect in meta-analysis with normally distributed responses
Hartung, J., & Knapp, G. (2001) · Statistics in Medicine · doi:10.1002/sim.791 · Cited by 543
Billioud, V., Sandborn, W. J., & Peyrin-Biroulet, L. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.60 · Cited by 433
Self-citationBonovas, S., Fiorino, G., Allocca, M., Lytras, T., Nikolopoulos, G. K., Peyrin-Biroulet, L., & Danese, S. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.04.039 · Cited by 387
Self-citationDing, N. S., Hart, A., & De Cruz, P. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13445 · Cited by 309
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
Wyant, T., Fedyk, E., & Abhyankar, B. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw092 · Cited by 284
Hazlewood, G. S., Rezaie, A., Borman, M., Panaccione, R., Ghosh, S., Seow, C. H., Kuenzig, E., Tomlinson, G., Siegel, C. A., Melmed, G. Y., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.011 · Cited by 276
Immunogenicity of biologics in inflammatory bowel disease
Vermeire, S., Gils, A., Accossato, P., Lula, S., & Marren, A. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x17750355 · Cited by 232
Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L., & Bonovas, S. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2403 · Cited by 195
Self-citationRosario, M., French, J. L., Dirks, N. L., Sankoh, S., Parikh, A., Yang, H., Danese, S., Colombel, J., Smyth, M. D. L., Sandborn, W. J., et al. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx021 · Cited by 171
Self-citationA Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab
Rosario, M., Dirks, N. L., Milch, C., Parikh, A., Bargfrede, M., Wyant, T., Fedyk, E., & Fox, I. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0546-0 · Cited by 158
Bonovas, S., Lytras, T., Nikolopoulos, G. K., Peyrin‐Biroulet, L., & Danese, S. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14449 · Cited by 152
Self-citationUngar, B., Kopylov, U., Yavzori, M., Fudim, E., Picard, O., Lahat, A., Coscas, D., Waterman, M., Haj-Natour, O., Orbach-Zingboim, N., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.11.050 · Cited by 126
Rosario, M., French, J. L., Dirks, N. L., Sankoh, S., Parikh, A., Yang, H., Danese, S., Colombel, J., Smyth, M. D. L., Sandborn, W. J., et al. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx168 · Cited by 123
Self-citationNovel therapeutic targets for inflammatory bowel disease
ARGOLLO, M. C., Fiorino, G., Hindryckx, P., Peyrin‐Biroulet, L., & Danese, S. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.07.004 · Cited by 120
Self-citationIn vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes
Wyant, T. L., Yang, L., & Fedyk, E. R. (2013) · mAbs · doi:10.4161/mabs.26392 · Cited by 60
Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease
Pouillon, L., Bossuyt, P. J., & Peyrin‐Biroulet, L. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1203897 · Cited by 58
Self-citationGhosh, S., Sandborn, W. J., Colombel, J., Feagan, B. G., Panaccione, R., Hanauer, S. B., Schreiber, S., Peyrin‐Biroulet, L., Vermeire, S., Eichner, S. F., et al. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000909 · Cited by 26
Self-citation
Cited by
Kobayashi, T., Siegmund, B., Le Berre, C., Wei, S. C., Ferrante, M., Shen, B., Bernstein, C. N., Danese, S., Peyrin-Biroulet, L., & Hibi, T. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0205-x · Cited by 1,649
Self-citation
Metadata
- Authors
- Peyrin-Biroulet, L., Danese, S., Argollo, M., Pouillon, L., Peppas, S., Gonzalez-Lorenzo, M., Lytras, T., & Bonovas, S.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 17
- Issue
- 5
- Pages
- 838-846.e2
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2809296974
- Cited by
- 181
- References
- 35
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.